Get started
AKEBIA THERAPEUTICS INCAKEBIA THERAPEUTICS INCAKEBIA THERAPEUTICS INC

AKEBIA THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

AX9 chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪221.80 M‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.21EUR
Net income (FY)
‪−47.04 M‬EUR
Revenue (FY)
‪176.33 M‬EUR
Shares float
‪192.27 M‬
Beta (1Y)
1.49

About Akebia Therapeutics, Inc.

Sector
Health Technology
CEO
John P. Butler
Headquarters
Cambridge
Website
akebia.com
Employees (FY)
167
Founded
2007
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of AX9 is 1.08 EUR — it has increased by 1.98% in the past 24 hours. Watch AKEBIA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AKEBIA THERAPEUTICS INC stocks are traded under the ticker AX9.
AX9 stock has fallen by 4.75% compared to the previous week, the month change is a 16.83% fall, over the last year AKEBIA THERAPEUTICS INC has showed a 4.04% increase.
We've gathered analysts' opinions on AKEBIA THERAPEUTICS INC future price: according to them, AX9 price has a max estimate of 5.54 EUR and a min estimate of 3.69 EUR. Watch AX9 chart and read a more detailed AKEBIA THERAPEUTICS INC stock forecast: see what analysts think of AKEBIA THERAPEUTICS INC and suggest that you do with its stocks.
AX9 reached its all-time high on Jun 23, 2014 with the price of 21.35 EUR, and its all-time low was 0.19 EUR and was reached on May 10, 2022. View more price dynamics on AX9 chart.
See other stocks reaching their highest and lowest prices.
AX9 stock is 3.74% volatile and has beta coefficient of 1.49. Track AKEBIA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is AKEBIA THERAPEUTICS INC there?
Today AKEBIA THERAPEUTICS INC has the market capitalization of ‪221.97 M‬, it has increased by 3.40% over the last week.
Yes, you can track AKEBIA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
AKEBIA THERAPEUTICS INC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
AX9 earnings for the last quarter are −0.08 EUR per share, whereas the estimation was −0.07 EUR resulting in a −25.06% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about AKEBIA THERAPEUTICS INC earnings.
AKEBIA THERAPEUTICS INC revenue for the last quarter amounts to ‪30.22 M‬ EUR despite the estimated figure of ‪42.71 M‬ EUR. In the next quarter revenue is expected to reach ‪45.61 M‬ EUR.
AX9 net income for the last quarter is ‪−16.67 M‬ EUR, while the quarter before that showed ‪555.38 K‬ EUR of net income which accounts for ‪−3.10 K‬% change. Track more AKEBIA THERAPEUTICS INC financial stats to get the full picture.
No, AX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 21, 2024, the company has 167.00 employees. See our rating of the largest employees — is AKEBIA THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AKEBIA THERAPEUTICS INC EBITDA is ‪1.63 M‬ EUR, and current EBITDA margin is −2.17%. See more stats in AKEBIA THERAPEUTICS INC financial statements.
Like other stocks, AX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AKEBIA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AKEBIA THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AKEBIA THERAPEUTICS INC stock shows the sell signal. See more of AKEBIA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.